MIM
AKBA icon

MetLife Investment Management’s Akebia Therapeutics AKBA Stock Holding History

MetLife Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128K Sell
92,270
-33,211
-26% -$45.6K ﹤0.01% 2429
2025
Q4 		$202K Sell
125,481
-9,675
-7% -$20.3K ﹤0.01% 2268
2025
Q3 		$369K Sell
135,156
-14,652
-10% -$48.7K ﹤0.01% 1956
2025
Q2 		$545K Buy
149,808
+31,644
+27% +$86.9K ﹤0.01% 1635
2025
Q1 		$227K Buy
118,164
+14,134
+14% +$28.9K ﹤0.01% 2129
2024
Q4 		$198K Buy
104,030
+35,966
+53% +$62.5K ﹤0.01% 2313
2024
Q3 		$89.8K Buy
68,064
+13,907
+26% +$18.6K ﹤0.01% 2666
2024
Q2 		$55.2K Buy
+54,157
New +$66.9K ﹤0.01% 2746
2022
Q2 		– Sell
-85,186
Closed -$61.2K – 2855
2022
Q1 		$61.2K Buy
85,186
+54,389
+177% +$116K ﹤0.01% 2667
2021
Q4 		$69.6K Sell
30,797
-32,929
-52% -$89.8K ﹤0.01% 2460
2021
Q3 		$184K Buy
63,726
+31,245
+96% +$89.2K ﹤0.01% 2153
2021
Q2 		$123K Sell
32,481
-28,415
-47% -$95.6K ﹤0.01% 2388
2021
Q1 		$206K Buy
60,896
+28,800
+90% +$104K ﹤0.01% 2037
2020
Q4 		$89.9K Buy
32,096
+3,799
+13% +$11.1K ﹤0.01% 2232
2020
Q3 		$71K Sell
28,297
-29,880
-51% -$262K ﹤0.01% 2254
2020
Q2 		$790K Buy
58,177
+5,951
+11% +$61.6K 0.01% 1126
2020
Q1 		$396K Buy
52,226
+10,611
+25% +$82.6K 0.01% 1331
2019
Q4 		$263K Sell
41,615
-15,711
-27% -$74.7K ﹤0.01% 1828
2019
Q3 		$225K Hold
57,326
– – ﹤0.01% 1877
2019
Q2 		$277K Buy
57,326
+16,718
+41% +$95.1K ﹤0.01% 1836
2019
Q1 		$333K Hold
40,608
– – ﹤0.01% 1702
2018
Q4 		$225K Buy
40,608
+19,179
+90% +$150K ﹤0.01% 1841
2018
Q3 		$189K Hold
21,429
– – ﹤0.01% 2118
2018
Q2 		$214K Hold
21,429
– – ﹤0.01% 1893
2018
Q1 		$204K Hold
21,429
– – ﹤0.01% 1880
2017
Q4 		$319K Buy
+21,429
New +$355K ﹤0.01% 1674

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

MetLife Investment Management's AKBA Position: Q1 2026 in Review

MetLife Investment Management reduced its Akebia Therapeutics (AKBA) stake by 26% in Q1 2026, selling an estimated $45.6K and leaving 92,270 shares worth $128K. The position accounts for ﹤0.01% of the portfolio, ranked #2429.

MetLife Investment Management first reported a position in AKBA in Q4 2017 and has held it in 26 quarters since. The position peaked at $790K in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • MetLife Investment Management held 92,270 shares of Akebia Therapeutics worth $128K as of Q1 2026.
  • MetLife Investment Management sold 33,211 Akebia Therapeutics shares in Q1 2026, an estimated $45.6K.
  • Akebia Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2429 holding.
  • MetLife Investment Management first reported a position in Akebia Therapeutics in Q4 2017 and has held it in 26 quarters since.
  • MetLife Investment Management's Akebia Therapeutics position peaked at $790K in Q2 2020.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.